People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Roka BioScience, Inc. | — | Biotechnology | Series B | $141.4M | $893.0M | 2016 |
Jonathan G. Silverstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan G. Silverstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Cohen | 1 | 12 |
| Jonathan Silverstein | 1 | 10 |
| Fred G. Cohen | 1 | 3 |
| Fred J Cohen | 1 | 2 |
| Michael P. Doyle | 1 | 2 |
| Paul Thomas | 1 | 2 |
| Nicholas G. Valeriani | 1 | 1 |
| Jim G. Barret, PhD | 1 | 1 |
| Steven T. Sobieski | 1 | 1 |
| Paul G. Thomas | 1 | 1 |
| Paul T. Thomas | 1 | 1 |
| Steven Sobieski | 1 | 1 |
| Josh Bilenker, MD | 1 | 1 |
| Jim Barret, PhD | 1 | 1 |
| Michael J. Watts | 1 | 1 |
| Lars Boesgaard | 1 | 1 |
| David G. McGirr | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.